Nothing Special   »   [go: up one dir, main page]

WO2000074667A3 - Compositions active in telomere damage comprising a taxane and telomerase inhibitor - Google Patents

Compositions active in telomere damage comprising a taxane and telomerase inhibitor Download PDF

Info

Publication number
WO2000074667A3
WO2000074667A3 PCT/US2000/015544 US0015544W WO0074667A3 WO 2000074667 A3 WO2000074667 A3 WO 2000074667A3 US 0015544 W US0015544 W US 0015544W WO 0074667 A3 WO0074667 A3 WO 0074667A3
Authority
WO
WIPO (PCT)
Prior art keywords
activity
telomere damage
taxane
compositions
telomerase inhibitor
Prior art date
Application number
PCT/US2000/015544
Other languages
French (fr)
Other versions
WO2000074667A2 (en
Inventor
Jessie L-S Au
Guillaume Wientjes
Original Assignee
Jessie L-S Au
Guillaume Wientjes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jessie L-S Au, Guillaume Wientjes filed Critical Jessie L-S Au
Priority to AU54665/00A priority Critical patent/AU5466500A/en
Publication of WO2000074667A2 publication Critical patent/WO2000074667A2/en
Publication of WO2000074667A3 publication Critical patent/WO2000074667A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)

Abstract

The invention provides methods and compositions for modulating the activity of therapeutic agents for the treatment of a cancer by administering one or more agents that (either alone or in combination) induces telomere damage and inhibits telomerase activity in the cancer cell. The method initially uses, e.g., a telomere damage-inducing agent such as paclitaxel, and a telomerase inhibitory agent such as AZT. The invention also provides methods for identifying other agents with telomere damage-inducing activity and/or telomerase inhibitory activity (as well as and compositions having such activity), for use in the treatment of cancer.
PCT/US2000/015544 1999-06-04 2000-06-05 Compositions active in telomere damage comprising a taxane and telomerase inhibitor WO2000074667A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU54665/00A AU5466500A (en) 1999-06-04 2000-06-05 Methods and compositions for modulating drug activity through telomere damage

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13754999P 1999-06-04 1999-06-04
US60/137,549 1999-06-04

Publications (2)

Publication Number Publication Date
WO2000074667A2 WO2000074667A2 (en) 2000-12-14
WO2000074667A3 true WO2000074667A3 (en) 2003-07-03

Family

ID=22477930

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/015544 WO2000074667A2 (en) 1999-06-04 2000-06-05 Compositions active in telomere damage comprising a taxane and telomerase inhibitor

Country Status (2)

Country Link
AU (1) AU5466500A (en)
WO (1) WO2000074667A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087286A2 (en) * 2000-05-17 2001-11-22 Avi Biopharma, Inc. Antisense enzyme inhibitors for improving pharmacokinetics of a drug
US7439271B2 (en) * 2001-06-27 2008-10-21 The Gillette Company Reduction of hair growth
EP1879657A2 (en) * 2005-04-25 2008-01-23 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of compounds to enhance processivity of telomerase

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996001835A1 (en) * 1994-07-07 1996-01-25 Geron Corporation Mammalian telomerase
WO1996041016A1 (en) * 1995-06-07 1996-12-19 Geron Corporation Methods for measuring telomere length
WO1997038013A1 (en) * 1996-04-09 1997-10-16 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
WO1999009212A1 (en) * 1997-08-18 1999-02-25 Queen Mary & Westfield College Telomerase assay

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996001835A1 (en) * 1994-07-07 1996-01-25 Geron Corporation Mammalian telomerase
WO1996041016A1 (en) * 1995-06-07 1996-12-19 Geron Corporation Methods for measuring telomere length
WO1997038013A1 (en) * 1996-04-09 1997-10-16 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
US6046307A (en) * 1996-04-09 2000-04-04 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
WO1999009212A1 (en) * 1997-08-18 1999-02-25 Queen Mary & Westfield College Telomerase assay

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HUMINIECKI L.: "Telomerase as therapeutic target", ACTA BIOCHIMICA POLONICA, vol. 43, no. 3, 1996, pages 531 - 538, XP000972359 *
KONDO YASUKO ET AL: "Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis", ONCOGENE,GB,BASINGSTOKE, HANTS, vol. 16, no. 17, 30 April 1998 (1998-04-30), pages 2243 - 2248, XP000864718, ISSN: 0950-9232 *
NEIDLE S. ET AL: "Commentary: Telomerase as an anti-cancer target. Current status and future prospects", ANTI CANCER DRUG DESIGN, vol. 14, 1999, pages 341 - 347, XP000972301 *

Also Published As

Publication number Publication date
AU5466500A (en) 2000-12-28
WO2000074667A2 (en) 2000-12-14

Similar Documents

Publication Publication Date Title
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
WO2004030627A3 (en) Synergistic methods and compositions for treating cancer
EP3530288A3 (en) Methods for treating conditions associated with masp-2 dependent complement activation
MXPA04006039A (en) Methods for the treatment of peripheral neural and vascular ailments.
EP1401479A4 (en) Detection and therapy of vulnerable plaque with photodynamic compounds
NO20060398L (en) Use of a combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for the treatment and inhibition of cancer
WO2002072031A3 (en) Substituted tetracycline compounds as synergistic antifungal agents
WO2006091395A3 (en) Inhibitors of akt activity
PL1682126T3 (en) Substituted benzazoles and use thereof as inhibitors of raf kinase
WO2000038665A3 (en) Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
MXPA03010085A (en) Composition and methods for treatment of hyperplasia.
WO2006135627A3 (en) Inhibitors of akt activity
MY133996A (en) Compounds for the treatment of ischemia
WO2001078783A3 (en) Compositions comprising natural agents for treatment of cancer
WO2001017543A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
EP1392328A4 (en) Cancer therapy
BR0011225A (en) Agent to treat dry eyes, its method and use
WO2002094189A3 (en) Compositions and methods for treating or preventing convulsions or seizures
WO2002036129A3 (en) Topical treatment of mastalgia with arometese inhibitors such as androstendione
TNSN07203A1 (en) Pharmaceutical compositions for the treatment of cellulite
WO2005060960A3 (en) Use of histamine to treat bone disease
WO2004093856A3 (en) Combination of a cox-2 inhibitor and an alkylating-type antineoplastic agent for treatment of neoplasia
WO2003012051A8 (en) Inhibitor of dna methylation
WO2002041831A3 (en) Inositol derivatives for increasing chloride secretion and inhibiting inflammation
WO2000074667A3 (en) Compositions active in telomere damage comprising a taxane and telomerase inhibitor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP